Abstract: A method for determining the magnitude of leakage in a subscriber's premises CATV installation; a frequency multiplexer for coupling between an antenna and a receiver for the multiplexed frequencies; and, a method for a technician to certify a CATV subscriber's premises for the provision of CATV services are disclosed.

Abstract: Described are methods for subcutaneously administering a therapeutic composition comprising a RNAi agent for inhibiting Receptor for Advanced Glycation End-products (AGER or RAGE). The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene when administered subcutaneously. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma. Subcutaneous delivery of the RAGE RNAi agents described herein can provide certain advantages over inhaled delivery.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: The water resistive barrier system may include a foam panel coupled to a frame of a building. The system may include a membrane above the foam panel. The system may include a scratch layer above the membrane. The system may include an exterior layer above the scratch layer. The system wherein the foam panel has a thickness between two and eight inches may have a structural tensile strength of 50 psi. In some embodiments, a method of manufacturing the water resistive barrier system may include providing a foam panel. The method may include coupling a membrane above the foam panel. The foam panel and the membrane can be manufactured as one panel. The method may include providing a scratch layer material for further coupling above the membrane during an installation. The method may include providing an exterior layer material for further coupling above a scratch layer during the installation.

Abstract: A method for determining the magnitude of leakage in a subscriber's premises CATV installation; a frequency multiplexer for coupling between an antenna and a receiver for the multiplexed frequencies; and, a method for a technician to certify a CATV subscriber's premises for the provision of CATV services are disclosed.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: A method for determining the magnitude of leakage in a subscriber's premises CATV installation; a frequency multiplexer for coupling between an antenna and a receiver for the multiplexed frequencies; and, a method for a technician to certify a CATV subscriber's premises for the provision of CATV services are disclosed.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a matrix metallopeptidase 7 (MMP7) gene. The MMP7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MMP7 gene. Pharmaceutical compositions that include one or more MMP7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MMP7 RNAi agents to pulmonary cells, in vivo, provides for inhibition of MMP7 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as idiopathic pulmonary fibrosis (IPF).

Abstract: A fuel filter monitoring method includes receiving pressure signals that are indicative of a pressure drop across at least one fuel filter of a fuel supply system configured to supply fuel to at least one fuel injector of an internal combustion engine and receiving a condition signal indicative of a condition of a fuel supply system, the condition signal being generated by one or more of a geographic location sensor, an altitude sensor, and/or a fuel temperature sensor. The method includes estimating a remaining life of at least one fuel filter of the fuel supply system based on the pressure signal and the condition signal and outputting a notification indicative of the estimated remaining life.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a beta-ENaC (SCNN1B) gene. The beta-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a beta-ENaC gene. Pharmaceutical compositions that include one or more beta-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described beta-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of beta-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including chronic obstructive pulmonary disease (COPD).

Abstract: In one aspect, a system for coupling a fuel rail of a common rail fuel system to an internal combustion engine may include an engine wall having a plurality of openings. The fuel rail may have a main pipe portion located outside the engine wall, and a plurality of outlet pipes monolithically formed with the main pipe portion, each of the plurality of outlet pipes extending into a corresponding one of the plurality of openings of the engine wall. The system may further include a seal located in sealing engagement with each of the plurality of openings and a corresponding outlet pipe.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Mucin 5AC (MUC5AC) gene. The MUC5AC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an MUC5AC gene. Pharmaceutical compositions that include one or more MUC5AC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MUC5AC RNAi agents to pulmonary epithelial cells, in vivo, provides for inhibition of MUC5AC gene expression and a reduction in MUC5AC production, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including mucoobstructive lung disease such as severe asthma and various cancers.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

Abstract: An instrument system for locating leakage at a subscriber's premises is disclosed.

Abstract: A fuel filter monitoring method includes receiving pressure signals that are indicative of a pressure drop across at least one fuel filter of a fuel supply system configured to supply fuel to at least one fuel injector of an internal combustion engine and receiving a condition signal indicative of a condition of a fuel supply system, the condition signal being generated by one or more of a geographic location sensor, an altitude sensor, and/or a fuel temperature sensor. The method includes estimating a remaining life of at least one fuel filter of the fuel supply system based on the pressure signal and the condition signal and outputting a notification indicative of the estimated remaining life.

Abstract: A method for determining the magnitude of leakage in a subscriber's premises CATV installation; a frequency multiplexer for coupling between an antenna and a receiver for the multiplexed frequencies; and, a method for a technician to certify a CATV subscriber's premises for the provision of CATV services are disclosed.

Abstract: A fuel filter monitoring method includes receiving pressure signals that are indicative of a pressure drop across at least one fuel filter of a fuel supply system configured to supply fuel to at least one fuel injector of an internal combustion engine and receiving a condition signal indicative of a condition of a fuel supply system, the condition signal being generated by one or more of a geographic location sensor, an altitude sensor, and/or a fuel temperature sensor. The method includes estimating a remaining life of at least one fuel filter of the fuel supply system based on the pressure signal and the condition signal and outputting a notification indicative of the estimated remaining life.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.